 Home > Active Ingredient News > Antitumor Therapy > ASCO 2021: Summary Overview and Prospects 20 | Special Research Express on Non-Small Cell Lung Cancer (03)

ASCO 2021: Summary Overview and Prospects 20 | Special Research Express on Non-Small Cell Lung Cancer (03)

 Last Update: 2021-06-04
 Source: Internet
 Author: User

Tags

acyclovir drug class

cell phone use

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The annual meeting of the American Society of Clinical Oncology (ASCO) will be held from June 4 to 8, 2021.

Lung cancer topic summary: Lung cancer topic summary:

ASCO 2021: Summary Overview and Prospects 14|Special Research Progress of Non-Small Cell Lung Cancer (02)

ASCO 2021: Summary Overview and Prospects 14|Special Research Progress Express of Non-Small Cell Lung Cancer (02) ASCO 2021: Summary Overview and Prospects 14|Special Research Progress Express of Non-Small Cell Lung Cancer (02)

ASCO 2021: Summary Overview and Outlook 13|Special Research Express on Non-Small Cell Lung Cancer (01)

ASCO 2021: Summary Overview and Outlook 13|Special Research Express of Non-Small Cell Lung Cancer (01) ASCO 2021: Summary Overview and Outlook 13|Special Research Express of Non-Small Cell Lung Cancer (01)

ASCO 2021: Summary Overview and Prospects 4｜Research Express in the Field of Small Cell Lung Cancer

Results of first, second and third generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases ( NSCLC BM)

Results of first, second and third generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases ( NSCLC BM) First, second and third generation anaplastic lymphoma kinase (ALK) Outcome of inhibitor in non-small cell lung cancer brain metastasis ( NSCLC BM) lymphoma NSCLC

Background: Non-small cell lung cancer (NSCLC) is the most common cause of brain metastases.

Background: Background: Non-small cell lung cancer (NSCLC) is the most common cause of brain metastases.

In this retrospective study, the overall survival (OS) and progression-free survival (PFS) of NSCLCBM patients treated with first, second, and third generation ALK inhibitors were investigated .

Methods: Methods evaluated : NSCLCBM patients between 2010 and 2019 .

Results: Results: A total of 90 patients had ALK gene rearrangements.

Conclusion: Conclusion: The new generation of targeted therapy in NSCLCBM improves the penetration rate of BBB and the effectiveness of anti-drug resistance mutations.

For details, see: Results of first, second and third generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastasis (NSCLCBM)

For details, see: Results of first, second and third generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastasis (NSCLCBM) First, second and third generation anaplastic lymphoma kinase ( ALK) inhibitor in non-small cell lung cancer brain metastasis (NSCLCBM) results

The results of the first and third representative skin growth factor receptor (EGFR) inhibitors in brain metastasis non-small cell lung cancer (NSCLCBM)

The results of the first and third generation of skin growth factor receptor (EGFR) inhibitors in brain metastasis of non-small cell lung cancer (NSCLCBM) The first and third generation of skin growth factor receptor (EGFR) inhibitors in brain metastasis Results in non-small cell lung cancer (NSCLCBM)

： (NSCLC) ，10-30% 。EGFR ， 50%NSCLC 。 EGFR(TKI)，， (BBB)20 (T790M) 。 EGFR TKI，， BBBT790M 。， EGFR TKINSCLCBM(OS)(PFS)。

：： (NSCLC) ，10-30% 。EGFR ， 50%NSCLC 。 EGFR (TKI)，， (BBB) 20 (T790M) 。 EGFR TKI，， BBB T790M 。， EGFR TKI NSCLCBM (OS) (PFS)。

： 2010 2019 NSCLCBM 。、。OS 。OS PFS Cox 。

：： 2010 2019 NSCLCBM 。、。OS 。OS PFS Cox 。

： 193 EGFR NSCLCBM 。33EGFREGFR TKI，56.

：： 193 EGFR NSCLCBM 。33EGFREGFR TKI，56.

：：NSCLCBM ， BBB 。，， mPFS ， NSCLCBM ，， mOS 。，，，。

EGFR TKI

： (EGFR) (NSCLCBM) 。

(EGFR) (NSCLCBM) 。

EGFR

EGFREGFR

：，EGFR（m+）NSCLC。 EGFR TKI 。EGFRm+ NSCLC，。

：：，EGFR（m+）NSCLC。 EGFR TKI 。EGFRm+ NSCLC，。

：NSCLC。EGFR TKI，4，A：EGFR TKI，B：EGFR TKI（CT），C：EGFR TKI，D：EGFR TKICT。。

：：NSCLC。EGFR TKI，4，A：EGFR TKI，B：EGFR TKI（CT），C：EGFR TKI，D：EGFR TKICT。。

：20171220205584EGFRm+NSCLC，228（39%）。，194pts。（2021 1 1 ），147 ，78 。A、B、C、DPFS11.

：：20171220205584EGFRm+NSCLC，228（39%）。，194pts。（2021 1 1 ），147 ，78 。A、B、C、DPFS11.

：：EGFRNSCLC，EGFR-TKI，，，EGFR-TKICT，，。ERGF-TKI，ORR，，。

：EGFR

EGFR

Comparison of the immune microenvironment between primary lung tumors and paired brain metastatic tumors

Paired primary lung tumors and brain metastases tumor immune microenvironment Comparative primary lung tumors and brain metastases paired tumor immune comparison microenvironment immune

Background: Lung cancer is one of the most common causes of brain metastases (BM) and is always associated with a poor prognosis.

Background: Background: Lung cancer is one of the most common causes of brain metastases (BM) and is always associated with a poor prognosis.

Methods: Methods: From 2000 to 2019 , 43 Chinese NSCLC patients were admitted to the hospital with BMs during treatment or during the course of the disease .

Results: Results: The data showed that compared with primary lung tumors, brain metastases showed reduced tumor infiltrating lymphocytes (TIL) (all 28 immune cell subtypes P <0.

Compared with primary lung tumors ( 47% ), the proportion ( 23% ) of TMITI (high PD-L1/ high CD8A ) in brain metastases was significantly reduced ( P <0.
05 ).
In addition, we found that three immunosuppressive checkpoint molecules, namely C10orf54 (VISTA) , CTLA4 and CD274 (PD-L1) were down-regulated in brain metastases than in primary lung tumors ( P <0.
001 and P <0.
001, respectively) , P = 0.
034 ).
In addition, the PD-L1 expression correlation between paired brain metastases and primary lung tumors was poor ( R=0.
28 , P=0.
068 ).
Unsupervised hierarchical cluster analysis showed that primary lung tumors have two different immune gene characteristic patterns, namely cluster A and cluster B.
The tumor immunity in cluster B is rich.

Conclusion: Our work illustrates the immunological landscape of NSCLC brain metastases and shows that compared with primary lung tumors, the tumor immune microenvironment in brain metastases is further immunosuppressed, which may help guide the immunotherapy of NSCLC brain metastases Strategy.

Conclusion: Conclusion: Our work illustrates the immune landscape of NSCLC brain metastasis, and shows that compared with primary lung tumors, the tumor immune microenvironment in brain metastasis is further immunosuppressed, which may help guide NSCLC brain metastasis Immunotherapy strategies.

For details, see: Comparison of the immune microenvironment between primary lung tumors and paired brain metastatic tumors

Comparison of the immune microenvironment between primary lung tumors and paired brain metastatic tumors

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.